(Access for IPA staff only)
There are (at least) 5 adult Pompe patients treated in Greece of which one did not benefit and stopped therapy.
Source:
Clin Neurol Neurosurg. 2011 Jan 6. [Epub ahead of print]
Adult Pompe disease: Clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy.
Papadimas GK, Spengos K, Konstantinopoulou A, Vassilopoulou S, Vontzalidis A, Papadopoulos C, Michelakakis H, Manta P.
Department of Neurology, University of Athens, School of Medicine, Eginition Hospital, Athens, Greece.
Abstract
OBJECTIVE: Pompe disease is an autosomal recessive lysosomal disorder caused by α-glucosidase deficiency. A specific treatment for the disease with enzyme replacement therapy is currently available. The aim of the present study is to describe the clinical manifestations and the effect of treatment in the first Greek patients with the adult form of the disease.
METHODS: Five Greek patients with adult onset Pompe disease aged between 40 and 73 years received 20mg/kg Myozyme intravenously at two weekly intervals over a different period. Clinical and functional parameters were longitudinally registered.
RESULTS: Proximal muscle weakness and respiratory insufficiency were the most common manifestations of the disease, but their severity was different even among patients with similar genotype. The effect of treatment varied with most patients experiencing some improvement in muscle strength and fatigability, while the most severely affected patient did not benefit and stopped therapy.
CONCLUSION: No clear genotype-phenotype correlation emerges from our study. The different effect of treatment on our patients seems to be mainly related to their pre-treatment condition and can be reliably assessed only on a long term basis.
Copyright © 2010 Elsevier B.V. All rights reserved.
PMID: 21216089 [PubMed – as supplied by publisher]